ghk-cu clinical trial injection human Peptide FDA scientists flag concerns with

Injection Techniques BPC-157 and TB500 are typically administered subcutaneously (subQ) near the injury site for local effect, or systemically (lower abdomen) for general recovery

The FDA reviewed TB-500 specifically for wound healing applications

BPC 157 has been shown to reduce the damage caused by brain ischemia, enhancing cognitive recovery and overall brain function

The peptide supports the healing of various tissues such as: skin tendon ligament muscle bone This broad spectrum of healing capabilities means that BPC 157 can be used in a variety of medical scenarios, from treating skin wounds to aiding in bone healing

For musculoskeletal indications, most patients at our Doral clinic report a noticeable reduction in pain within 2 to 3 weeks and a functional improvement (range of motion, strength, load tolerance) by weeks 4 to 8